NYSE: VTR · Healthcare Facility REITs
Ventas (VTR) fair value: undervalued or overvalued?
As of 16 Nov 2026, Faircurve's model values Ventas (VTR) at $46.80 a share. The stock last closed at $88.90, which puts the model's fair value 47.4% below the price. On the model's bands that reads as Overvalued.
Revalued . Price is the close of 16 Nov 2026. Ventas, Inc.
The report adds the live price, the chart against the range the options market prices and the next earnings date. No account needed.
This week, in three parts
What happenedThe run of 16 Nov 2026 moved the fair value from $43.01 to $46.80 (+8.8%). The model does not yet explain moves on this valuation method.
What the model makes of itThe price of $88.90 is 47.4% above it: Overvalued, on a high evidence grade.
What's nextNext report on 4 Feb 2027. Options prices imply a move of about 9% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give VTR?
The calibrated range for VTR over 63 trading days is $80.50 to $98.67. It sits around the last close, and its width comes from the volatility that VTR's own options imply (30% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own range is $43.11 to $51.02.
Faircurve Insights · 16 Nov 2026
Ventas, Inc. is an S&P 500 company enabling exceptional environments that benefit a large and growing aging population. It has approximately 1,450 properties in North America and the United Kingdom.
The model's fair value for Ventas is $46.80 a share, as run on 16 Nov 2026. The previous run, on 7 Nov 2026, gave $43.01, so the fair value moved +8.8%. The model does not yet explain moves on this valuation method. The calibrated range over 63 trading days is $81.21 to $97.80, built around the price from the volatility the stock's own options imply. The range is calibrated weekly against realised prices, refreshed 14 Nov 2026. Ranges built this way held the price 60% of the time at this horizon. The evidence grade is High. For REITs, the grade looks at the dividend record, meaning at least three years of paid dividends with no cut. It does not say whether the fair value is right.
The sheet holds no quality score for Ventas against its peers. Faircurve compares Ventas with Omega Healthcare Investors, Inc. (OHI), Healthpeak Properties, Inc. (DOC), CareTrust REIT, Inc. (CTRE), Healthcare Realty Trust Incorporated (HR), Sabra Health Care REIT, Inc. (SBRA) and LTC Properties, Inc. (LTC). American Healthcare REIT, Inc. (AHR) and Welltower Inc. (WELL) are also compared, with no verdict on this date. Faircurve first valued Ventas on 4 Jul 2026.
Written from the figures on this page for the 16 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does VTR report earnings, and how has the stock reacted?
Ventas's next earnings report is scheduled for 4 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 7.0% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. VTR's 30 day implied volatility works out to about 8.7% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across VTR's last 8 reports, ignoring direction, was 5.7%.
What the options market has priced for a month's move in VTR
How does VTR compare with similar companies?
The companies in healthcare facility reits closest to Ventas in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| OHI Omega Healthcare Investors, Inc. | $47.08 | $51.39 | +9.2% | Undervalued |
| DOC Healthpeak Properties, Inc. | $19.84 | $31.13 | +56.9% | Undervalued |
| AHR American Healthcare REIT, Inc. | $58.07 | $22.90 | -60.6% | Gap wider than 60% |
| WELL Welltower Inc. | $244.78 | $75.03 | -69.3% | Gap wider than 60% |
| CTRE CareTrust REIT, Inc. | $37.39 | $33.28 | -11.0% | Overvalued |
| HR Healthcare Realty Trust Incorporated | $19.32 | $17.48 | -9.5% | Overvalued |
| SBRA Sabra Health Care REIT, Inc. | $20.35 | $20.72 | +1.8% | Fairly valued |
| LTC LTC Properties, Inc. | $42.71 | $56.30 | +31.8% | Undervalued |
All healthcare facility reit stocks ranked by gap to fair value
Ventas at a glance
Ventas, Inc. is an S&P 500 company enabling exceptional environments that benefit a large and growing aging population. With approximately 1,450 properties in North America and the United Kingdom, Ventas occupies an essential role in the longevity economy.
- Market value
- $47.0B
- Sector
- Real Estate
- Industry
- Healthcare Facility REITs
- Beta to the US market
- -0.13
- First valued by Faircurve
- 4 Jul 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. VTR was not among them.
How the fair value is worked out: the model values Ventas three ways and blends them; the range around the fair value comes from 2,000 simulations of the dividend model. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for VTR was $43.01. As of 16 Nov 2026 it is $46.80, a change of +8.8%. The model does not yet explain moves on this valuation method. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Ventas's valuation
Is Ventas stock undervalued or overvalued?
On Faircurve's model, VTR reads as Overvalued as of 16 Nov 2026. The model's fair value is $46.80 a share against a last close of $88.90, a gap of -47.4%.
What is VTR's fair value?
$46.80 a share as of 16 Nov 2026. The fair value blends three methods: a cash-flow multiple against comparable companies, a dividend model, and the value of the properties. The model's own range is $43.11 to $51.02.
What price range does the model give VTR?
$80.50 to $98.67 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Ventas report earnings next?
The next report is scheduled for 4 Feb 2027. Companies can move their dates.
How much has VTR moved on past earnings reports?
Across its last 8 reports the median two session move was 5.7%, ignoring direction. The largest was -7.3% around the report of 27 Oct 2026.
How confident is the model in this valuation?
The model's evidence grade for VTR is high. For real estate investment trusts (REITs) the grade looks at the dividend record: at least three years of paid dividends with no cut. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on VTR
The model holds no idea open on VTR today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on VTR with their outcomes. A free account is enough.